奥沙利铂联合卡培他滨或替吉奥对晚期结肠癌患者疗效对比

目的 探究奥沙利铂联合卡培他滨或替吉奥对晚期结肠癌患者的治疗效果.方法 选取晚期结肠癌患者112例,依据抽签法将患者分为卡培他滨组和替吉奥组,每组各56例;给予卡培他滨组患者奥沙利铂联合卡培他滨进行化疗,给予替吉奥组患者奥沙利铂联合替吉奥进行化疗.观察比较两组患者治疗前后的白细胞计数(WBC)、血小板计数(PLT)、miRNA(miR-21)水平及恶心呕吐、手足综合征(HFS)、口腔黏膜炎、肝功能异常发生率,并比较两组疗效.结果 治疗前两组患者的WBC、PLT及miR-21水平比较,差异无统计学意义(P﹥0.05);治疗后两组患者WBC、PLT及miR-21水平较本组治疗前均降低,组间比较卡培他滨组患者的PLT高于替吉奥组,差异有统计学意义(P﹤0.05);治疗过程中卡培他滨组患者HFS及恶心呕吐发生率高于替吉奥组,差异有统计学意义(P﹤0.05);两组患者的总有效率比较,差异无统计学意义(P﹥0.05).结论 奥沙利铂联合卡培他滨或替吉奥均可对晚期结肠癌患者起到明显治疗效果,两者均可作为结肠癌的临床治疗方案.

The effect of oxaliplatin combined with capecitabine or S-1 in patients with advanced colon cancer

Objective To explore the effect of oxaliplatin combined with capecitabine or tegafur/gimeracil/oteracil potassium (S-1) in patients with advanced colorectal cancer. Method 112 cases of patients with advanced colon cancer were included in the study, and were given capecitabine (n=56) or S-1 (n=56) in combination with oxaliplatin by simple randomization. The WBC and PLT count, miR-21 level, and the incidence of nausea and vomiting, hand-foot syndrome (HFS), oral mucositis, abnormal liver function of the two groups were compared. Result The level of WBC, PLT and miR-21 were of no significant differences between the two groups before treatment (P>0.05), while were significantly de-creased after treatment in both groups, and patients in the capecitabine group had higher PLT count than that of the S-1 group (P<0.05); And higher incidence of HFS and nausea and vomiting was observed in capecitabine group compared with S-1 group (P<0.05); Though the overall response rate was similar between the two groups (P>0.05). Conclusion Oxaliplatin combined with capecitabine or S-1 are effective therapies for patients with advanced colon cancer, and both regimes are applicable in clinical practice.